This study is testing a medicine called lanreotide to see if it helps prevent a problem called a pancreatic fistula after surgery. A pancreatic fistula is a leak from the pancreas that can cause infections. Patients with pancreatic cancer or lesions may have surgery to remove part of their pancreas. Lanreotide, given before surgery, might stop these leaks better than surgery alone. Lanreotide is similar to a hormone our bodies make and can stop certain hormones that help tumors grow.

• The study lasts about a year, with follow-ups at 4, 8, and 12 months after surgery.
• Participants will get either lanreotide or a placebo shot before surgery and have blood tests during the study.
• The study involves some risks, such as possible side effects from lanreotide.

Adults with pancreatic cancer or lesions who are planning to have surgery may join this study. They must not have taken certain medications or treatments recently. Participants will need to agree to use birth control if they can have children. They will also be asked to fill out some quality-of-life questionnaires. Participation is voluntary, and consent is required. This study will help researchers understand if lanreotide can make surgery safer for pancreatic patients.